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Abstract
Background: Malignant brain tumors affect people of all ages and are the second leading cause of cancer deaths
in children. While current treatments are effective and improve survival, there remains a substantial need for more
efficacious therapeutic modalities. The ketogenic diet (KD) - a high-fat, low-carbohydrate treatment for medically
refractory epilepsy - has been suggested as an alternative strategy to inhibit tumor growth by altering intrinsic
metabolism, especially by inducing glycopenia.
Methods: Here, we examined the effects of an experimental KD on a mouse model of glioma, and compared
patterns of gene expression in tumors vs. normal brain from animals fed either a KD or a standard diet.
Results: Animals received intracranial injections of bioluminescent GL261-luc cells and tumor growth was followed
in vivo. KD treatment significantly reduced the rate of tumor growth and prolonged survival. Further, the KD
reduced reactive oxygen species (ROS) production in tumor cells. Gene expression profiling demonstrated that the
KD induces an overall reversion to expression patterns seen in non-tumor specimens. Notably, genes involved in
modulating ROS levels and oxidative stress were altered, including those encoding cyclooxygenase 2, glutathione
peroxidases 3 and 7, and periredoxin 4.
Conclusions: Our data demonstrate that the KD improves survivability in our mouse model of glioma, and
suggests that the mechanisms accounting for this protective effect likely involve complex alterations in cellular
metabolism beyond simply a reduction in glucose.
Background
Brain tumors will kill ~13,000 people in the US this year,
and they are the second leading cause of cancer deaths in
children and young adults [1]. Despite currently available
treatments, the median survival remains approximately
1 year following diagnosis. Thus, it is of paramount
importance that novel and more efficacious therapies be
developed for brain cancer patients. One approach is to
exploit the metabolic dysregulation seen in tumors which
makes them rely preferentially on glucose as an energy
source. In support of this concept, the high-fat ketogenic
diet (KD) and caloric restriction, both of which reduce
blood glucose, have been shown to reduce tumor prolif-
eration in mouse astrocytoma models [2]. Furthermore,
two recent case studies [3-5] have suggested that a KD
may be a useful therapeutic modality in patients. How-
ever, the anti-neoplastic mechanisms underlying such
dietary interventions are incompletely understood.
One of the hallmark features of the KD is the increased
production of the ketone bodies (i.e., b-hydroxybutyrate
[BHB] and acetoacetate [ACA]) which serve as alternative
fuels [6], and which have recently been shown to reduce
reactive oxygen species (ROS) production in brain [7].
ROS are multi-faceted effector molecules involved in
numerous cellular pathways, including those regulating
autophagic/apoptotic responses to genotoxic stress,
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any medium, provided the original work is properly cited.hypoxia and nutrient deprivation. Cancer cells often have
increased levels of ROS [8] which have been implicated
in angiogenesis induction and tumor growth through the
regulation of vascular endothelial growth factor (VEGF)
and hypoxia-inducible factor 1 (HIF-1) [9]. In the present
study, we examined the effects of an experimental KD in
a mouse model of glioma, and found that the KD indeed
reduces ROS levels in tumor tissue, and importantly,
alters the expression of genes involved in the cellular
response to oxidative stress.
Methods
GL261 mouse model of glioma
GL261 cells were obtained from DCTD Tumor Reposi-
tory (NCI, Frederick, MD) and grown in DMEM supple-
mented with 10% fetal calf serum (FCS) at 37°C with
5% CO2. Cells were harvested by trypsinization, washed
in DMEM without FCS, resuspended at a concentration
of 1-2 × 10
7 cells/ml in DMEM without FCS and
implanted into female C57BL/6 mice (Jackson Labora-
tories, Bar Harbor, ME) as described [10]. Each experi-
ment consisted of 20 mice. Mice were propagated in the
animal care facility of St. Joseph’s Hospital and Medical
Center in rooms with controlled temperature and
humidity under a 12-hour light-dark cycle. Animals
were weighed daily to ensure that all the animals were
gaining weight in an equivalent manner. Animals were
euthanized at the occurrence of visible symptoms of
impending death such as hunched posture, reduced
mobility and visible body weight loss [11].
To facilitate a quantitative measurement of tumor
growth rate GL261 cells were made bioluminescent using
the Lentiphos™ HT System (Clontech Laboratories, Inc.,
Mountain View, CA) with the Lenti-X™ HT Packaging
Mix (Clontech Laboratories, Inc.) and the FUW-GL plas-
mid (a generous gift from the laboratory of J.B. Rubin,
MD, PhD). GL261-luc cells were maintained in DMEM
with 10% tetracycline-free FCS (Clontech Laboratories,
Inc.). Female C57BL/6-cBrd/cBrd/Cr strain, obtained
from the National Cancer Institute Frederick Animal
Production Program (Frederick, MD), was used for
experiments using GL261-luc cells. Animals received an
i.p. or subcutaneous (s.c.) injection of 150 μg luciferin/kg
body weight 15 min prior to imaging. In vivo imaging
was done using an IVIS® Spectrum in vivo imaging sys-
tem (Caliper Life Sciences, Hopkinton, MA). Tumor cells
were detectable from the day of implantation and quanti-
tation was done using the system’s Living Image® 3.1
software.
Ketogenic diet
Following surgery, animals were fed standard rodent
chow for 3 days. Treatment groups were then assigned
to remain on regular rodent chow or switch to the
ketogenic Bio-Serv F3666 diet (Bio-serv, Frenchtown,
NJ) ad libitum a sd e s c r i b e db yR h oa n dc o w o r k e r s
[12,13]. This diet consists of 8.36% protein, .76% carbo-
hydrates and 78.8% fat (173.3 g/Kg casein, 586.4 g/kg
cellulose, 586.4 g/kg shortening (Crisco) and vitamins
and minerals equal to that found in normal rodent
chow). Serum b-hydroxybutyrate levels were determined
each week using a Keto-Site reflectance meter (GDS
Diagnostics, Elkhart, IN) and blood glucose levels were
tested using a HemoCue Glucose 201 System (Hemo-
Cue USA, Lake Forest, CA) on blood obtained from tail
clips to ensure maintenance of ketonemia and to deter-
mine if there was a drop in blood glucose.
Measurement of Reactive Oxygen Species (ROS
The fluorescent oxidation products of dihydroethidium
(DHE, Sigma-Aldrich®)w e r eu s e dt od e m o n s t r a t eR O S
production in vivo, specifically the superoxideo radical.
DHE was dissolved in 10% dimethylsulfoxide (DMSO) in
PBS and warmed to 40°C. Twenty-seven mg/kg was
injected i.p. in a total of 200 μl 18 hours prior to imaging.
DHE fluorescence was imaged in vivo using an excitation
wavelength of 500 nm and an emission wavelength of
620 nm. Spectral unmixing was used to differentiate the
DHE signal from autofluorescence. Bioluminescence of
the tumor cells was measured as described above.
In vitro quantitative ROS measurements were made
on cultured GL261 cells and ex vivo measurements were
made on tumor slices. Cultured cells were treated with
a cocktail containing either 2 mM or 10 mM total
ketones as described above prior to in vitro analysis.
Ex vivo analysis was done on brain slices containing
tumor from animals sacrificed prior to the occurrence
of visible symptoms but at least 1 week after the start of
the KD. Both cultured cells and brain slices were incu-
bated for 60 min in a standard solution of 145 mM
NaCl, 4 mM KCl, 2 mM CaCl2,1m MM g C l 2,1 0m M
glucose, 10 Mm HEPES, 320-330 mOsm Tris pH 7.4
containing 20 μM2 ’,7’-dichlorofluorescein diacetate
(DCFDA) to measure ROS as described. Cell fluores-
cence was normalized to background (i.e., cell-free area)
and the fluorescence was quantified on an open scale
using a value of 0 to represent the absence of detectable
signal [7,14].
Gene expression analysis
Total cellular RNA was isolated from the tumor and the
non-tumor containing contralateral side of the brain using
the TRIzol® LS Reagent (Invitrogen Corp., Carlsbad, CA)
and conditions specified by the manufacturer. Tumor was
dissected away from as much non-involved brain as possi-
ble prior to extraction. Non-tumor containing contralat-
eral side consisted of the contalateral cortex - an area that
did not have tumor cells detectable by histology or
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R N A s e - f r e eD N a s eu s i n gt h eD N A -free™ Kit (Ambion,
Inc., Austin, TX) and the quality of the sample was ascer-
tained using an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Palo Alto, CA). Each condition was done in
duplicate using two separate animals.
Analysis was performed by the National Institutes of
Neurological Disorders and Stroke (NINDS) microarray
core facility at the University of California, Los Angeles
using the Affymetrix GeneChip® M o u s eG e n o m e4 3 0
2.0 array (Affymetrix, Santa Clara, CA). RNA processing
and hybridization to the microarrays was performed as
recommended by the manufacturer. Hybridized arrays
were scanned in a GeneChip Scanner 3000 (Affymetrix)
and analyzed with GeneChip Operating Software
(GCOS) v1.1 (Affymetrix) was used to perform global
scaling to bring the overall intensities of the arrays to a
target intensity value of 150. This eliminates biological
differences, as well as differences in washings and stain-
ing, allowing for inter-array comparisons. The correla-
tion coefficients for the replicate samples were 0.978 for
non-tumor samples from animals fed KD, 0.983 for the
tumor samples from the animals fed KD, 0.985 for the
non-tumor samples from the animals fed SD and 0.993
for the tumor samples from the animals fed SD. Signal
values and detection calls were generated in GCOS v1.1
using the Statistical Algorithm, data was imported into
GeneSpring 7.3.1 (Agilent Technologies) and each gene
was normalized to the median measurement for that
gene. Genes showing ≥2-fold difference in expression
were used for further analysis.
Statistical methods
Survival plots used Kaplan-Meier analysis and a Gehan-
Breslow-Wilcoxon test. Affymetrix genechip data was
analyzed for quality by correlation coefficients across
replicates and by measuring the 95
th %ile fold-change
across technical replicates. The fold-change method is
an estimate of the minimal detectable fold-change when
only 2 replicates are available [15].
Results
The ketogenic diet prolongs survival and inhibits the
growth of gliomas in vivo
We chose the GL261-C57/BL6 syngeneic intracranial
tumor model for this work because it has been used in
a number of preclinical therapeutic studies [10,16,17].
This model recapitulates many of the characteristics of
human high-grade tumors including invasion, necrosis
and pseudopalisading, immunopositivity to GFAP and
S100, angiogenesis, high proliferative index, upregulation
of vascular endothelial growth factor (VEGF) and
hypoxia-inducible factor 1 [alpha] (HIF1[alpha]) around
zones of necrosis, mutations in p53 and K-ras,u p
regulation of c-myc and p53, and activation of the PI3K
pathway as indicated by phosphorylation of Akt [18,19].
The cells have point mutations in the genes encoding
K-ras and p53 and a subpopulation of cells are positive
for CD133 and exhibit a stem cell-like phenotype [20].
MRI scans on days 9 and 15 post-implantation demon-
strated tumor growth over time (Figure 1). There was no
significant difference in the rate of weight gain between
the control animals and the tumor bearing animals regard-
less of diet SD or KD (data not shown). Animals fed the
KD did show a statistically significant (p = 0.0067) increase
in BHB levels (Figure 2) as expected. Kaplan-Meier analy-
sis of the survival data using a Gehan-Breslow-Wilcoxon
test demonstrated a statistically significant increase
(P value of .0196) in survival of animals fed the KD
(Figure 3). Tumors were evident in all of the animals on
necropsy (data not shown). Brain and tumor tissue was
snap frozen in liquid nitrogen for future molecular studies.
The prolonged survival seen in animals fed a KD
could be due to a general inhibition of tumor growth, or
it could be due to a cytostatic effect of the KD resulting
in a lag in tumor growth that was then overcome by the
selection of cells resistant to the effects of the diet. The
kinetics of tumor growth was demonstrated using
GL261-luc cells and in vivo imaging. Tumor size was
determined every three days following implantation
until the animals became symptomatic and were sacri-
ficed. Figure 4 demonstrates that the rate of tumor
growth was slowed in animals fed the KD.
Ketones reduce reactive oxygen species in tumor cells in
vitro and in vivo
Previous studies in rat neocortical neurons supported
the idea that the effect of ketone bodies is primarily
through the reduction in ROS [7,14]. To demonstrate
the ability of ketones to quantitatively reduce ROS in
cultured GL261 cells, we treated them with either
2 mM BHB/ACA or 10 mM BHB/ACA for 24 hr prior
to ROS analysis using 20 μM2 ’,7 ’-dichlorofluorescein
diacetate (DCF). Tumor cells had high levels of ROS as
determined by DCF fluorescence, and the application of
either 2 mM or 10 mM ketones resulted in a statistically
significant (p ≤ 0.001) decrease in the DCF signal,
demonstrating the quantitative reduction of ROS in
these cells (Figure 5A).
The presence of increased ROS in the area of the
GL261-luc glioma in a mouse maintained on SD was
demonstrated using a combination of in vivo fluores-
cent detection of ROS using DHE and bioluminescent
detection of the tumor (Figure 5B). While in vivo ana-
lyses suggested reduced the levels of ROS in animals
fed KD (data not shown), it was difficult to obtain a
quantitative in vivo measure of ROS due to the overlap
in emission wavelengths between the DHE and the
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analyses on brain slices from animals implanted with
GL261-luc cells and sacrificed 2 weeks following
implantation. The core of the tumor and the invading
front where the tumor intersects with normal brain
were analyzed (Figure 5C). There is a statistically sig-
nificant (p ≤ 0.05) reduction of ROS levels in tumors
Figure 1 MRI demonstrates the presence of tumors. MRI scans were done on tumor-bearing mice on days 9 and 15. Animals were
positioned onto a probe in a head first, prone position. A T2 weighted MRI at 4.7 Tesla was obtained on 16 coronal sections of the animal’s
frontal lobe at a slice thickness of 0.5 mm.
Figure 2 Animals fed the ketogenic diet showed an increase in
blood BHB levels. There was a statistically significant difference by
2-way ANOVA (p = 0.0067) in blood BHB levels in animals fed KD
versus SD. There was no difference in the results obtained at the 2
different time points. Five animals were used per condition and the
results are shown as the mean ± SEM.
Figure 3 Animals fed a ketogenic diet had a statistically
significant increase in survival following tumor implantation.
The number in parentheses is the number of animals in each
treatment group.
Stafford et al. Nutrition & Metabolism 2010, 7:74
http://www.nutritionandmetabolism.com/content/7/1/74
Page 4 of 11from animals fed a KD relative to those fed a SD in
b o t ht h ec o r ea n dt h ei n v a d i n gf r o n to ft h et u m o r .I t
is of interest that while there is an overall reduction of
ROS in tumors from animals fed a KD, we sometimes
found cells or small foci of cells that appeared to have
a higher level of ROS than the surrounding brain (Fig-
ure 5C, arrows). Brain tumors are known to be hetero-
geneous, and this may represent cells that are resistant
to ROS reduction. The data was obtained from 6 cell
line experiments and 10 brain slices analyzed using a
one-way ANOVA followed by the Tukey test (post-
hoc). Data shown is the mean ± SEM.
Expression profiling analysis
RNA from the tumor and contralateral normal brain
was analyzed from 2 animals fed a KD and 2 animals
maintained on standard rodent chow. The replicate
samples were highly reproducible (≥0.978). A compari-
son of tumor and normal brain from animals fed a KD
demonstrated differential expression of 1129 genes out
of the 43,972 transcripts represented on the GeneChip®
Mouse Genome 430 2.0 array. Differential expression of
1015 genes was seen in animals maintained on a SD. Of
these, 614 genes were common to both gene lists.
A two-way ANOVA for interaction was done (Figure 6).
The data from the tumor sample obtained from mice
fed a SD is clearly separate from the data obtained from
the other three conditions. This analysis implies that the
KD is driving the overall gene expression in the tumor
to be more normal, that is, to be more like gene expres-
sion seen in the non-tumor containing tissue.
Since the neuroprotective action of the KD is thought
to be due, at least in part, to a reduction in ROS and we
demonstrated a reduction in ROS in tumors from ani-
mals fed KD, we analyzed the expression of genes
involved in ROS metabolism and oxidative stress based
on their inclusion in the gene list from the Mouse “Oxi-
dative Stress and Antioxidant Defense” RT
2 Profiler PCR
Array from SABiosciences Corp. (Frederick, MD). This
84-gene list includes peroxidases, genes involved in ROS
metabolism and oxygen transporter genes. We first ana-
lyzed the difference in the ratio of gene expression in
tumor versus normal brain from animals fed KD versus
S D( F i g u r e7 A ,T a b l e1 ) .A2 - f o l dd i f f e r e n c ei ne x p r e s -
sion for at least one of the diets was used as a cutoff,
and 9 genes satisfied these criteria. In all cases the effect
of the diet was opposite in animals fed SD versus KD.
Genes that were over-expressed in tumor versus normal
b r a i ni na n i m a l sf e daS D( Serpinb1b, Cygb, Mpp4 and
Ptgs2) were under-expressed in tumor from animals fed
a KD. Conversely, genes that were under-expressed in
tumor versus normal brain in animals fed a SD (Cyba,
Noxo1, Prdx4 and Gpx7) were over-expressed in tumor
from animals fed a KD.
These data suggested that the effect of diet was differ-
ent in normal brain versus tumor. We therefore com-
pared the effect of diet on normal brain and the effect
of the diet on tumor (Figure 7B, Table 1). Twenty-one
genes were found to have at least a 2-fold difference in
expression in tumor or normal brain from animals fed
SD compared to KD. The effect of diet appears to be
more pronounced in normal tissue versus tumor tissue.
In normal tissue the KD led to the over-expression of
10 genes (Ptgs2, S e r p i n b 1 b ,C y g b ,N g b ,S r x n 1 ,N q o 1 ,
Prnp, Mpp4, Gpx3 and Scd1) relative to SD. Eleven
genes were higher in normal brain from animals fed SD
compared with KD (Gsr, Txnip, Gstk1, Ncf2, Txnrd1,
Vim, Cyba, Noxo1, Prdx4 and Gpx7). Diet had a much
less pronounced effect on gene expression in tumor
tissue than it did in normal brain. In fact, only one gene
(Ptgs2) showed more than a 2-fold difference in expres-
sion between animals fed SD versus KD.
Discussion
I nt h ep r e s e n ts t u d y ,w eu s e dab i o l u m i n e s c e n tm o u s e
model of malignant glioma to demonstrate that a KD
can: (1) significantly retard tumor growth; (2) prevent
increases in ROS associated with tumor growth; and (3)
shift overall gene expression in tumor tissue to a pattern
seen in normal brain. When compared to the expression
profile in normal brain, the KD exerts differential effects
in brain tumor tissue, and appears to influence specific
genes involved in regulation of ROS levels. Taken
Figure 4 T u m o rg r o w t hi na n i m a l sf e das t a n d a r dd i e t( b l a c k
circle) or a ketogenic diet (blue square). Animals were
randomized to a treatment arm on day 3 post-implantation.
Bioluminescence (photon count) was measured every 3 days.
Results are an average of 5 animals for each diet.
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isms likely involve complex alterations in cellular meta-
bolism beyond a simple reduction in blood glucose, as
previously hypothesized [21,22].
The KD is a high-fat, low carbohydrate diet that has
been successfully used to treat medically refractory epi-
lepsy for many decades, particularly in children [23].
Intriguingly, recent studies have highlighted potential
uses for other neurological disorders [21,24-29]. With
respect to brain tumors, Seyfried and co-workers
[2,21,30,31] demonstrated that the KD or caloric restric-
tion could extend survival in a mouse model of astrocy-
toma, and proposed that glucose restriction may be the
critical factor, despite a multiplicity of other potential
mechanisms [2,21,30-32]. Specifically, while normal
brain cells may readily adapt to using ketone bodies as
an alternative source of energy, tumor cells are less
metabolically flexible. There are myriad reasons for this
difference, and changes in gene expression may affect
other aspects of glycolysis, respiration and mitochondrial
function [21,33,34].
To explore other mechanisms, we used a biolumines-
cent GL261/C57BL/6 mouse model system in which the
KD extends survival in a manner similar to that seen in
the CT-A model system used by Seyfried [30,31,35].
Serial in vivo imaging of these tumors demonstrated
that the KD slowed the overall rate of growth of these
tumors, rather than increasing survival by selecting for a
subpopulation of cells less influenced by the dietary
change. To gain further insight into this observation, we
undertook gene expression studies, and compared the
profiles to previous studies involving KD treatment in
normal rodent brain.
Noh et al [36] studied the hippocampus of normal
juvenile mice using a Rat Atlas 1.2 Array II cDNA
expression array (Clontech Laboratories) containing
Figure 5 Ketones reduced ROS levels. (A) Cells were treated with a cocktail containing either 1 mM (total 2 mM ketones) or 5 mM each (total
10 mM ketones) BHB and AcA for 24 hr prior to analysis. ROS levels were analyzed using DCF as described in the methods. Untreated tumor
cells had high levels of ROS, and the application of either 2 mM or 10 mM ketones resulted in a dose dependent statistically significant decrease
in the DCF signal demonstrating a reduction of ROS. (* = p ≤ 0.05), (** = p ≤ 0.001); (B) The presence of increased reactive oxygen species (ROS)
in tumor and the surrounding area relative to normal tissue is shown in a mouse fed a standard diet. Dihydroethidium (DHE) was imaged using
an excitation wavelength of 500 nm and an emission wavelength of 620 nm. Spectral unmixing was used to differentiate the DHE signal from
autofluorescence (shown in purple). The tumor was visualized using bioluminescence (shown in green); (C) Photomicrograph of brain slices from
animals fed standard diet (SD) or ketogenic diet (KD). Areas from the tumor core and invading front of the tumor are shown. DCF fluorescence
was analyzed as described in the methods section. There is a statistically significant difference in the amount of ROS in tumor vs normal brain
when animals fed a standard diet were compared to those fed the ketogenic diet. (* = p ≤ 0.05); N.S. = not significant.
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expressed after KD treatment, and interestingly, most
encoded proteins are ordinarily involved in mitochon-
drial metabolic and intracellular signal transduction
pathways. Similarly, Bough et al [37] analyzed the effect
of a calorie-restricted KD versus SD fed ad libitum on
gene expression in the hippocampi of normal male rats.
They reported up-regulation of genes encoding elements
of oxidative phosphorylation and other mitochondrial
proteins, as well as some involved in mitochondrial
biogenesis. Yet other investigators have studied the
expression of genes involvedi nm e t a b o l i s mu s i n gv a r -
ious diets [38], anti-diabetic drugs [39] and genetically
altered mice [40].
While there is a dearth of information regarding the
mechanisms underlying the putative anti-neoplastic
effects of the KD, a number of studies have provided
insights into the neuroprotective properties of the diet,
and in particular, the role that ROS plays [7,13,41]. This
observation was of interest to us since ROS are known
to be effector molecules involved in numerous intracel-
lular pathways, including those regulating cellular autop-
hagic/apoptotic responses to genotoxic stress, hypoxia
and nutrient deprivation [9,42-46]. Additionally,
increased levels of ROS [8] can lead to induction of
angiogenesis and tumor growth through regulation of
vascular endothelial growth factor (VEGF) and hypoxia-
inducible factor 1 (HIF-1) [9]. Several signal transduc-
tion cascades activated by tyrosine kinase receptors act
in part through ROS-dependent mechanisms [8], and
Akt activation by ROS may support tumor cell survival
under hypoxic conditions [47]. Finally, ROS may even
contribute to the heterogeneity seen in brain tumors
because of its differential effects in normoxic vs. hypoxic
areas of a tumor [8].
We found that our GL261 cells did indeed exhibit
high ROS levels, and when maintained in vitro,
responded with a significant reduction in ROS upon
addition of ketones (Figure 5). Consistently, in vivo ima-
ging demonstrated increased ROS in tumor tissue from
animals fed a SD (Figure 5B) and ex vivo analysis
demonstrated the significant reduction of ROS in tumor
tissue from animals fed a KD (Figure 5C). While the
majority of the tumor showed ROS levels consistent
with normal brain in animals fed a KD, it was of interest
that a few cells appeared to maintain higher levels of
Figure 6 The KD alters overall gene expression to more closely resemble that seen in normal brain. Eight microarrays were analyzed by
2-way ANOVA for interaction effects, using standard Bonferonni multiple testing correction. There were strong interactions between ketogenic
diet and normal diet in non-tumor classes, especially in context of standard diet non-tumor. The trend is that many expression profiles in tumor
mice on a ketogenic diet seem to trend back to a profile seen with mice living on a standard diet having no tumor.
Stafford et al. Nutrition & Metabolism 2010, 7:74
http://www.nutritionandmetabolism.com/content/7/1/74
Page 7 of 11ROS. This may be a reflection of the heterogeneity seen
in these tumors. However, it is unlikely that these cells
are clinically relevant because no increases in ROS-posi-
tive cells were observed over time. Thus, despite the
presence of these cells, the many functions of ROS
suggest possible pathways through which the KD may
affect tumor growth other than alterations in glucose
availability.
Given the pivotal role that ROS seemed to play in
tumors as a response to the KD, we focused our analysis
of gene expression patterns on specific genes involved in
modulation of oxidative stress and antioxidant defense
pathways. Our statistical analysis revealed that the KD
did not substantially alter gene expression in normal
mouse brain; however, overall expression in tumor tis-
sue was affected such that it resembled that seen in nor-
mal brain issue (Figure 6). Moreover, genes that were
over-expressed in tumor relative to non-tumor tissue in
animals fed a SD were under-expressed in tumor rela-
tive to normal tissue in animals fed a KD (Figure 7B).
When we independently analyzed the effect of diet on
tumor vs. normal tissue, it was evident that non-tumor
tissue generally had a much more robust response to
diet than did tumor tissue (Figure 7A).
One prominent gene in our analyses is Ptgs2 (Cox2).
We found that Cox2 expression was reduced to non-
tumor levels when animals are fed a KD (Figure 7B).
This was particularly intriguing as Cox2 inhibition is
being explored as a treatment strategy for brain tumors
[48-51]. Inhibition of Cox2 has been correlated with
increased apoptosis in some systems and has been asso-
ciated with decreased endothelial cell spreading, migra-
tion and angiogenesis [48-52]. These data are consistent
with a previous report that the KD increased apoptosis
and inhibited angiogenesis [30].
Other genes involved in oxidative stress responses
were also affected by the KD, including glutathione
peroxidase 7 (Gpx7)a n dperoxiredoxin 4 (Prdx4), both
of which play cellular protective roles [53,54], and are
similarly regulated as Cox2 - i.e., showing higher expres-
sion in tumor vs. normal tissue when animals are fed a
KD, but not when they are fed a SD. Ziegler et al [55]
reported an increase in the activity of the Gpx enzyme
in the hippocampus of normal rats fed a KD, but not in
the cortex of cerebellum. This study did not examine
gene expression profiles, nor did it separate out the iso-
forms of the Gpx enzyme.
In contrast to Gpx7 and Prdx4, cytoglobin (Cygb)-
which also protects cells against oxidative stress [56] -
was more highly expressed in tumor vs. non-tumor
tissue in animals fed a SD, as well as in normal brain
when mice were fed a KD. Cytoglobin also encodes a
tumor suppressor protein [57], and this may help
explain why its expression is higher in tumor tissue
from animals fed SD, but lower in tumor tissue from
animals fed a KD.
Yet another potentially significant player is Nox
organizing protein 1 (NOXO1) which is required for
ROS generation by Nox1, along with the NOX activating
protein 1 (NOXA1) [58]. It is not clear why the expres-
sion of this gene is higher in tumor than in normal
brain in animals fed KD, and why SD-fed animals show
higher expression in non-tumor tissue. Adding further
complexity is the protein encoded by cytochrome b245,
alpha polypeptide (Cyba), which directly interacts with
both NOXO1 and NOX1, which in turn leads to the
production of H2O2. The expression of Cyba changes
with diet and tissue type in a manner identical to the
gene encoding NOXO1. Thus, there are a number of
genes involved in the formation of ROS through the
Nox system, and we cannot rule out the possibility that
the KD is less effective at reducing the production of
ROS through this mechanism.
Finally, animals fed a KD showed higher expression
the gene encoding the serine (or cysteine) peptidase
Figure 7 Expression of genes with significant differential
expression in animals fed a KD versus SD. Log2 expression levels
of genes that have ≥2-fold expression in at least one condition
ratio. 95% confidence intervals are shown.
Stafford et al. Nutrition & Metabolism 2010, 7:74
http://www.nutritionandmetabolism.com/content/7/1/74
Page 8 of 11inhibitor, clade B, member 1b (Serpinb1b), a putative
antioxidant enzyme [59]. This was particularly evident
in non-tumor tissue when compared to that seen in ani-
mals fed SD; however, Serpinb1b expression was higher
in KD-fed normal mice, whereas in the tumor groups,
animals fed a SD exhibited higher levels. The reason for
this difference is not yet clear, but at present, very little
is known about the function of this gene product.
Conclusions
We have shown that the KD, which induces ketonemia,
enhances survival in an animal model of malignant
glioma, possibly through a reduction in ROS to levels
seen in normal brain. Detailed gene expression analyses
have revealed that the KD caused overall gene expres-
sion to mirror that seen in non-tumor brain tissue. This
phenomenon was underscored when genes involved in
oxidative stress responses from the various treatment
groups were individually analyzed and compared.
Furthermore, the effect of the diet on gene expression
was more pronounced in non-tumor tissue than it was
in tumor tissue. The differential effects on gene expres-
sion in the tumor vs. the normal brain suggest that the
KD may not only be useful in the treatment of brain
tumors, but may also serve a protective function for
normal brain tissue during tumor treatment. Finally, our
data indicate that the effect of the KD on tumor growth
is not simply due to a reduction in available glucose and
is more likely to be due to complex interactions
amongst a number of gene networks that regulate
important intracellular signaling cascades and cellular
homeostatic mechanisms.
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Table 1 Genes with significant differential expression in animals fed a KD versus those fed SD
SD Expression KD Expression
Gene Symbol Gene Name Non-Tumor Tumor Non-Tumor Tumor
Ptgs2 (Cox2) Prostaglandin-endoperoxide synthase 2 (cyclooxygenase 2) 0.732 ± 0.035 0.364 ± 0.01 13.19 ± 5.24 0.41 ± 0.20
Cyga Cytochrome b-245, alpha polypeptide 5.5 ± 10.86 10.24 ± 0.05 3.79 ± 0.41 13.3 ± 1.31
Cygb Cytoglobin 8.02 ± 0.06 1.20 ± 0.09 6.53 ± 0.62 1.96 ± 0.01
Gpx3 Glutathione peroxidase 3 9.72 ± 1.33 4.75 ± 0.62 13.16 ± 0.75 5.72 ± 0.54
Gpx7 Glutathione peroxidase 7 2.82 ± 0.14 15.1 ± 0.91 2.18 ± 0.35 23.5 ± 3.07
Gstk1 Glutathione S-transferase kappa 1 8.36 ± 1.13 13.21 ± 1.51 5.83 ± 0.43 13.79 ± 0.56
Ncf2 Neutrophil cytosolic factor 2 1.04 ± 0.02 2.63 ± 0.30 1.31 ± 0.06 3.53 ± 0.25
Ngb Neuroglobin 3.01 ± 0.02 0.922 ± 0.10 4.06 ± 0.13 1.61 ± 0.01
Noxo1 NADPH oxidase organizer 1 0.56 ± 0.00 1.54 ± 0.31 0.46 ± 0.01 1.54 ± 0.03
Nqo1 NAD(P)H dehydrogenase, quinone 1.75 ± 0.10 0.85 ± 0.03 1.71 ± 0.01 0.744 ± 0.01
Prdx4 Peroxiredoxin 4 2.71 ± 0.21 14.04 ± 0.11 2.48 ± 0.41 19.68 ± 4.01
Prnp Prion protein 74.09 ± 0.04 21.46 ± 1.43 70.42 ± 9.03 23.17 ± 6.71
Scd1 Stearoyl-Coenzyme A desaturase 1 163.1 ± 5.1 83.65 ± 0.15 163.3 ± 22.16 88.54 ± 4.41
Serpinb1b Serine (or cysteine) peptidase inhibitor, clade B, member 1b 2.91 ± 0.11 0.39 ± 0.15 3.12 ± 1.53 0.41 ± 0.13
Srxn1 Sulfiredoxin 1 homolog (S. cerevisiae) 0.56 ± 0.00 0.068 ± 0.01 1.17 ± 0.05 0.88 ± 0.02
Txnip Thioredoxin interacting protein 9.82 ± 1.31 19.66 ± 1.15 8.71 ± 0.46 23.3 ± 1.56
Txnrd1 Thioredoxin reductase 1 15.17 ± 2.54 64.70 ± 1.71 15.69 ± 1.85 46.67 ± 1.33
Vim Vimentin 15.17 ± 2.23 160.60 ± 3.31 55.58 ± 10.12 140.3 ± 2.24
Expression values are normalized to the 50
th percentile per array.
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